In This Issue

1067 In This Issue of Diabetes Care

Editor’s Commentary

1069 Diabetes Care: “Lagniappe” and “Seeing Is Believing”!

Commentaries

1072 Islet Transplantation for Hypoglycemia Unawareness/Severe Hypoglycemia: Caveat Emptor
D.M. Harlan

1075 Clinical Trials, Triumphs, and Tribulations of Glucagon Receptor Antagonists
M.J. Pearson, R.H. Unger, and W.L. Holland

1078 Reevaluation of CMS’ Competitive Bidding Program
D. Schatz and W.T. Cefalu

Diabetes Care Symposium

This section features six articles from the Diabetes Care Symposium “Novel Clinical Strategies in the Management of Diabetes,” held in conjunction with the ADA’s 76th Scientific Sessions in New Orleans, 10–14 June 2016.

1080 NIH Precision Medicine Initiative: Implications for Diabetes Research
J.E. Fradkin, M.C. Hanlon, and G.P. Rodgers

1085 Precision Medicine in Diabetes: Is It Time?
J.C. Florez

1089 Persistent Effects of Intensive Glycemic Control on Retinopathy in Type 2 Diabetes in the Action to Control Cardiovascular Risk in Diabetes (ACCORD) Follow-On Study: The Action to Control Cardiovascular Risk in Diabetes Follow-On (ACCORDION) Eye Study Group and the Action to Control Cardiovascular Risk in Diabetes Follow-On (ACCORDION) Study Group

1103 CV Protection in the EMPA-REG OUTCOME Trial: A “Thrifty Substrate” Hypothesis
E. Ferrannini, M. Mark, and E. Mayoux

1111 Can a Shift in Fuel Energetics Explain the Beneficial Cardiorenal Outcomes in the EMPA-REG OUTCOME Study? A Unifying Hypothesis
S. Mudaliar, S. Alloju, and R.R. Henry

The Artificial Pancreas in 2016: A Digital Treatment Ecosystem for Diabetes

1123 The Artificial Pancreas in 2016: A Digital Treatment Ecosystem for Diabetes
B. Kovatchev, W.V. Tamborlane, W.T. Cefalu, and C. Cobelli

1127 Mitigating Meal-Related Glycemic Excursions in an Insulin-Sparing Manner During Closed-Loop Insulin Delivery: The Beneficial Effects of Adjunctive Pramlintide and Ligulirazole

1135 Randomized Crossover Comparison of Personalized MPC and PID Control Algorithms for the Artificial Pancreas

1143 Multinational Home Use of Closed-Loop Control Is Safe and Effective

1151 Day-and-Night Closed-Loop Glucose Control in Patients With Type 1 Diabetes Under Free-Living Conditions: Results of a Single-Arm 1-Month Experience Compared With a Previously Reported Feasibility Study of Evening and Night at Home

1161 Design Considerations for Artificial Pancreas Pivotal Studies
S.J. Russell and R.W. Beck

1168 Day-and-Night Hybrid Closed-Loop Insulin Delivery in Adolescents With Type 1 Diabetes: A Free-Living, Randomized Clinical Trial

1175 Outcome Measures for Artificial Pancreas Clinical Trials: A Consensus Report

1180 Randomized Summer Camp Crossover Trial in 9- to 13-Year-Old Children: Outpatient Wearable Artificial Pancreas Is Feasible and Safe

Diabetes Care Expert Forum

1186 Update and Next Steps for Real-World Translation of Interventions for Type 2 Diabetes Prevention: Reflections From a Diabetes Care Editors’ Expert Forum

Clinical Care/Education/Nutrition/Psychosocial Research

1202 Cognitive Dysfunction: Part and Parcel of the Diabetic Foot
Epidemiology/Health Services Research
1208 Relative Contributions of Socioeconomic, Local Environmental, Psychosocial, Lifestyle/Behavioral, Biophysiological, and Ancestral Factors to Racial/Ethnic Disparities in Type 2 Diabetes
R.S. Piccolo, S.V. Subramanian, N. Pearce, J.C. Florez, and J.B. McKinlay

1218 Seasonal Changes in the Prevalence of Gestational Diabetes Mellitus
R.G. Moses, V.C.K. Wong, K. Lambert, G.J. Morris, and F. San Gil

1222 Disability-Free Life-Years Lost Among Adults Aged ≥50 Years With and Without Diabetes

Emerging Technologies and Therapeutics
1230 Phase 3 Trial of Transplantation of Human Islets in Type 1 Diabetes Complicated by Severe Hypoglycemia

1241 Evaluation of Efficacy and Safety of the Glucagon Receptor Antagonist LY2489021 in Patients With Type 2 Diabetes: 12- and 24-Week Phase 2 Studies

Pathophysiology/Complications
1250 Maternal Serum Prolactin and Prediction of Postpartum β-Cell Function and Risk of Prediabetes/Diabetes

Cardiovascular and Metabolic Risk
1259 Dynamic Changes in Renal Function Are Associated With Major Cardiovascular Events in Patients With Type 2 Diabetes
S. Ragot, P.-J. Saulnier, G. Velho, E. Gand, A. de Haitrecloque, Y. Slaoui, L. Potier, P. Sosser, J.-M. Halimi, P. Zaouli, V. Rigalleau, F. Fumeron, R. Roussel, M. Murre, and S. Hadjadj, on behalf of the SURDAGENE and DIABHYCAR study groups

1267 Cardiovascular Mortality in Patients With Type 2 Diabetes and Recent Acute Coronary Syndromes From the EXAMINE Trial

Meta-analysis
1274 Prognostic Value of Coronary Computed Tomography Angiography in Patients With Diabetes: A Meta-analysis

Point-Counterpoint
1281 Should Restrictions Be Relaxed for Metformin Use in Chronic Kidney Disease? No, We Should Never Again Compromise Safety!
K. Kalantar-Zadeh and C.P. Kovesky

1287 Should Restrictions Be Relaxed for Metformin Use in Chronic Kidney Disease? Yes, They Should Be Relaxed! What’s the Fuss?
G.L. Bakris and M.E. Molitch

Clinical Images in Diabetes
1292 Presumptive Type 1 Diabetes With Comorbidities and Rapid Progression Despite Numerous Insulin-Positive Islets
L.M. Jacobsen, M.A. Atkinson, M. Campbell-Thompson, and D.A. Schatz

Issues and Events
1295 Issues and Events

e-Letters – Observations
1290 IADPSG and WHO 2013 Gestational Diabetes Mellitus Criteria Identify Obese Women With Marked Insulin Resistance in Early Pregnancy

1293 HbA1c-Based Classification Reveals Epidemic of Diabetes and Prediabetes in Vietnam
L.T. Ho-Pham, T.T. Do, L.V. Campbell, and T.V. Nguyen

1295 Nocturnal Hypoglycemia and Physical Activity in Children With Diabetes: New Insights By Continuous Glucose Monitoring and Accelerometry
S. Bachmann, M. Hess, E. Martin-Diener, K. Denhaerynck, and U. Zumsteg

1297 Exhaled Breath Isoprene Rises During Hypoglycemia in Type 1 Diabetes
S. Neupane, R. Pererall, G. Richmond, T.P.J. Blaikie, D. Taylor, G. Hancock, and M.L. Evans

e99 Evaluating the Quality of Comprehensive Cardiometabolic Care for Patients With Type 2 Diabetes in the U.S.: The Diabetes Collaborative Registry

e-Letters – Comments and Responses
102 Comment on Mita et al. Sitagliptin Attenuates the Progression of Carotid Intima-MediaThickness in Insulin-Treated Patients With Type 2 Diabetes: The Sitagliptin Preventive Study of Intima-Media Thickness Evaluation (SPIKE): A Randomized Controlled Trial. Diabetes Care 2016;39:455–464
M.I. Maiorino, G. Bellastella, D. Giugliano, and K. Esposito

T. Mita, N. Katakami, I. Shimomura, and H. Watada